Filing Flows › Comparisons › ABCL vs IMNM
AbCellera Biologics vs Immunome: ABCL and IMNM compared
AbCellera Biologics is the larger company: $4.0M of revenue in its latest quarter (Q2 2026) against $4.0M for Immunome (Q2 2025). Immunome is growing faster (+70% against -76% a year earlier).
Where the money goes: ABCL and IMNM
AbCellera Biologics (ABCL) · Q2 2026
AbCellera Biologics, Q2 2026: revenue $4.0M (-76% year over year), net loss $55.4M, operating cash flow $25.9M. The chart follows the revenue to costs, profit and cash.
Immunome (IMNM) · Q2 2025
Immunome, Q2 2025: revenue $4.0M (+70% year over year), net loss $43.4M, operating cash flow −$49.4M. The chart follows the revenue to costs, profit and cash.
| AbCellera Biologics (ABCL) | Immunome (IMNM) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2025 |
| Revenue | $4.0M | $4.0M |
| Revenue growth, Y/Y | -76% | +70% |
| Operating margin | n/m | n/m |
| Net earnings | −$55.4M | −$43.4M |
| Operating cash flow | $25.9M | −$49.4M |
| Free cash flow | $23.8M | — |
| Market value | $3.8B | — |
| Analysts’ mean target | $17.17 | — |
Where the revenue comes from
AbCellera Biologics
- Research fees: $3.9M (96%)
- Licensing and royalty revenue: $149K (4%)
Questions
Which is bigger, AbCellera Biologics or Immunome?
AbCellera Biologics is the larger company: $4.0M of revenue in its latest quarter (Q2 2026) against $4.0M for Immunome (Q2 2025).
Is AbCellera Biologics or Immunome growing faster?
Immunome is growing faster (+70% against -76% a year earlier).
More: AbCellera Biologics earnings · how AbCellera Biologics makes money · Immunome earnings · how Immunome makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed Aug 6, 2025). Fiscal quarters can end on different dates. Not investment advice.